Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1990 Jun;45(6):447–450. doi: 10.1136/thx.45.6.447

Controlled trial of natamycin in the treatment of allergic bronchopulmonary aspergillosis.

D C Currie 1, C Lueck 1, H J Milburn 1, C Harvey 1, J L Longbottom 1, J H Darbyshire 1, A J Nunn 1, P J Cole 1
PMCID: PMC462527  PMID: 2203181

Abstract

Allergic bronchopulmonary aspergillosis often requires treatment with oral corticosteroids to control the host response to Aspergillus fumigatus. In a double blind study 25 patients with allergic bronchopulmonary aspergillosis taking maintenance oral corticosteroids were randomly allocated to receive 5 mg natamycin or placebo by nebuliser twice daily for one year. The primary aim of the study was to assess the steroid sparing potential of natamycin. Standardised reductions in corticosteroid dosage were therefore undertaken every five weeks, unless clinically contraindicated. Five patients were withdrawn in the first four months: two (1 natamycin, 1 placebo) died, two (1 natamycin, 1 placebo) had suspected drug reactions, and one (natamycin) was non-compliant. The pretreatment characteristics of the 20 patients (10 in each group) who completed the study were similar, 17 (9 natamycin, 8 placebo) having evidence of recent disease activity. At the end of the study prednisolone dose had been reduced by a similar amount in each group (median natamycin 2.25 mg, placebo 2.5 mg). Evidence of disease activity during the study year (transient shadowing on the chest radiograph, blood eosinophilia, or increases in antibodies to A fumigatus, or any combination of these) was observed in similar numbers of patients in each group (5 natamycin, 7 placebo). There was no evidence that natamycin conferred benefit on these patients with allergic bronchopulmonary aspergillosis.

Full text

PDF
447

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. EDWARDS G., LATOUCHE C. J. THE TREATMENT OF BRONCHOPULMONARY MYCOSES WITH A NEW ANTIBIOTIC--PIMARICIN. Lancet. 1964 Jun 20;1(7347):1349–1353. doi: 10.1016/s0140-6736(64)92038-0. [DOI] [PubMed] [Google Scholar]
  2. Henderson A. H., Pearson J. E. Treatment of bronchopulmonary aspergillosis with observations on the use of natamycin. Thorax. 1968 Sep;23(5):519–523. doi: 10.1136/thx.23.5.519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Imbeau S. A., Nichols D., Flaherty D., Dickie H., Reed C. Relationships between prednisone therapy, disease activity, and the total serum IgE level in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 1978 Aug;62(2):91–95. doi: 10.1016/0091-6749(78)90084-2. [DOI] [PubMed] [Google Scholar]
  4. Lake-Bakaar G., Scheuer P. J., Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J (Clin Res Ed) 1987 Feb 14;294(6569):419–422. doi: 10.1136/bmj.294.6569.419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Maunsell K., Pearson R. S., Livingstone J. L. Long-term corticosteroid treatment of asthma. Br Med J. 1968 Mar 16;1(5593):661–665. doi: 10.1136/bmj.1.5593.661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. McCarthy D. S., Robertson D. G. Antifungal agents in bronchopulmonary aspergillosis. Lancet. 1968 May 18;1(7551):1089–1090. doi: 10.1016/s0140-6736(68)91439-6. [DOI] [PubMed] [Google Scholar]
  7. Mullins J., Harvey R., Seaton A. Sources and incidence of airborne Aspergillus fumigatus (Fres). Clin Allergy. 1976 May;6(3):209–217. doi: 10.1111/j.1365-2222.1976.tb01899.x. [DOI] [PubMed] [Google Scholar]
  8. PEPYS J., RIDDELL R. W., CITRON K. M., CLAYTON Y. M., SHORT E. I. Clinical and immunologic significance of Aspergillus fumigatus in the sputum. Am Rev Respir Dis. 1959 Aug;80:167–180. doi: 10.1164/arrd.1959.80.2.167. [DOI] [PubMed] [Google Scholar]
  9. Rosenberg M., Patterson R., Roberts M. Immunologic responses to therapy in allergic bronchopulmonary aspergillosis: serum IgE value as an indicator and predictor of disease activity. J Pediatr. 1977 Dec;91(6):914–917. doi: 10.1016/s0022-3476(77)80889-5. [DOI] [PubMed] [Google Scholar]
  10. Shale D. J., Faux J. A., Lane D. J. Trial of ketoconazole in non-invasive pulmonary aspergillosis. Thorax. 1987 Jan;42(1):26–31. doi: 10.1136/thx.42.1.26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Smyllie H. C., Connolly C. K. Incidence of serious complications of corticosteroid therapy in respiratory disease. A retrospective survey of patients in the Brompton hospital. Thorax. 1968 Nov;23(6):571–581. doi: 10.1136/thx.23.6.571. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES